Licensing | Partnership

Premium Programs and People

Talem is an extension of the CRO and takes antibody discovery to the next level. Gain access to a vault of next-generation, fully-human antibodies to streamline your path to the clinic.

High-value Targets

Talem preclinical experts match high value targets to fully vetted, premium antibody programs. Catapult your discovery project past the launch phase and accelerate to clinical success. Select from key targets for multiple indications, for licensing or co-development, including:

  • Discovery, preclinical and IND-enabling antibody programs
  • A broad range of indications: immuno-oncology, oncology, COVID-19, ophthalmology, inflammation, immunology, infectious, rare/neglected, autoimmune, heart diseases
  • Co-development of Talem internal, de novo and partner-specific programs

The expertise at Talem is the culmination of 30 years of combined experience, thousands of programs, greater than 500 clients worldwide (including 70% of the top 20 pharmaceutical companies) and a unique HUB of intelligence to guide you to the clinic.

Transgenic Animals at Talem

Our optimized, powerful custom species-agnostic technologies for use with transgenic animal platforms enable the discovery of highly diverse, fully human antibodies with superior clinical safety and efficacy and the lowest immunogenicity.

The ability to select very specific, “needle-in-a-haystack” human antibodies with this advanced combination offers an entirely new approach. Talem is the only CRO affiliate to offer these services in partnership with OmniAb® transgenic animals, using their own license.

The PolyTope® Advantage

Talem has been actively involved in SARS-CoV-2 research since January 2020. One of its most advanced development programs, TATX-03 (anti-SARS-CoV-2 PolyTope antibody cocktail), is a rationally designed, fully human, 4-antibody cocktail containing potently neutralizing antibodies against non-overlapping epitopes on SARS-CoV-2. Talem’s SARS-CoV-2 PolyTope therapy is designed to reduce mutagenic escape risk with an emphasis on efficacy for every patient, variant, and strain of SARS-CoV-2, and has been developed with the goal of sustainable efficacy as the virus evolves, combining broadly characterized, neutralizing and synergistic antibodies that exhibit diverse epitope coverage.

Polytope TATX-03 Additional Information

Partner with Talem

Talem is focused on the discovery and development of next-generation, fully human, monoclonal, therapeutic antibodies targeted toward any disease indication.

Along with direct access to world-class, expedited and end-to-end technologies in antibody discovery, characterization, manufacturing and engineering, Talem accelerates novel, therapeutic antibody treatments to the clinic through strategic alliances and partnerships.